What is Erchonia?
Founded in 1996, Erchonia Corporation has evolved from a family business into an international enterprise, maintaining its core principles of integrity and diligence. The company is dedicated to the scientific and clinical advancement of Low Level Laser Therapy (3LT®), positioning itself as a world leader in LLLT technology. Erchonia's rigorous process, from research hypothesis to agency-approved products, highlights its comprehensive approach as a manufacturer, marketer, developer, promoter, creator, and user of its proprietary technologies.
How much funding has Erchonia raised?
Erchonia has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Erchonia?
The recent strategic investment signifies Erchonia's robust position in the medical technology sector and its readiness for further expansion. As a company deeply invested in research and development, this capital infusion is expected to fuel continued innovation in LLLT applications and potentially broaden its market reach. Erchonia's commitment to scientific validation suggests a future focused on clinical trials and regulatory approvals, solidifying its leadership in the therapeutic laser market.
See full Erchonia company page
